Thursday, August 17, 2017 6:02:12 PM
8th International Congress "Sepsis and Multiorgan Dysfunction"
Sept 6-8
Abstract
During the last two decades, multiple treatment modalities have been tested in the attempt to improve clinical outcomes from sepsis. During this period we have consistently observed initially promising results that have gradually faded in subsequent large clinical trials. Researchers blame this irreproducibility on slow patient accrual (selection bias), the Hawthorn effect (knowing you are being watched changes your practice), beta-type errors (false positive), publication bias and other factors. In a recent publication (Mebazaa et al. Journal of Intensive Care (2016) 4:24) the authors stated, that the major reasons for lack of survival in recent sepsis trials are over-estimated treatment effects, suboptimal pre-clinical models, incorrect treatment targets, and heterogeneity of definitions and patients. Priorities for future sepsis clinical trials are among others, identification of responders to treatment, networks of sepsis investigators experienced in clinical trial conduct, application of the recent S-3 definitions for sepsis and septic shock, targeted clinical trials in relatively homogeneous groups of patients, and pre-specified covariate adjustment of the primary endpoint (heterogeneity) and exclusion of low-risk patients.
The German Sepsis Society (DSG) will address these questions at its 8th Weimar Sepsis Congress entitled ‘‘Facing the Challenges’’. Why Weimar? Due to its unique features, the Weimar Sepsis Congress has built up a reputation on a national and international level: leading experts from all over the world with excellent publications in basic and clinical research, no parallel sessions—everything under a single roof—vivid discussions in a smooth and casual atmosphere. The 8th Weimar Congress—that will once again take place together with the 9th Congress of the German Society of Intensive Nursing Care—will update you on the current state of knowledge about how to improve treatment of patients by adhering to the guidelines but yet in a critical way.
H. Gerlach
T. Welte
F. M. Brunkhorst
Frank Brunkhorst, Jena, Germany has been the chair at the annual Cytosorbents User Group and is an internationally renowned sepsis researcher who oversees the Cytosorb patient registry at University of Jena and Herwig Gerlach, Berlin, Germany has been a presenter at the User Group as well as ISCEM symposiums on the use of Cytosorb therapy. Both individuals will also be presenters:
Cytokine adsorption in septic shock – Background, rationale and latest data
H. Gerlach, Berlin, Germany
CytoSorb in clinical practice – Individualize your treatment
Z. Molnar, Szeged, Hungary
The CytoSorb Registry – Evidence from real life clinical use
F. Brunkhorst, Jena, Germany
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM